Edition:
India

Dicerna Pharmaceuticals Inc (DRNA.OQ)

DRNA.OQ on NASDAQ Stock Exchange Global Select Market

14.85USD
11 Oct 2019
Change (% chg)

$0.68 (+4.80%)
Prev Close
$14.17
Open
$14.29
Day's High
$15.00
Day's Low
$14.22
Volume
153,328
Avg. Vol
147,894
52-wk High
$16.95
52-wk Low
$9.40

Latest Key Developments (Source: Significant Developments)

Biospecifics Technologies Names J. Kevin Buchi As CEO
Thursday, 10 Oct 2019 

Oct 10 (Reuters) - Biospecifics Technologies Corp ::BIOSPECIFICS TECHNOLOGIES CORP. NAMES J. KEVIN BUCHI AS CHIEF EXECUTIVE OFFICER.BIOSPECIFICS TECHNOLOGIES CORP - KEVIN BUCHI WILL ALSO SERVE ON COMPANY'S BOARD OF DIRECTORS.BIOSPECIFICS TECHNOLOGIES CORP - BUCHI IS CURRENTLY CHAIRMAN OF BOARD OF DIRECTORS AT DICERNA PHARMACEUTICALS.  Full Article

Dicerna Q2 Loss Per Share $0.35
Friday, 9 Aug 2019 

Aug 8 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA™ REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.35.Q2 REVENUE $5.7 MILLION.Q2 REVENUE ESTIMATE $10.3 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-0.31 -- REFINITIV IBES DATA.DICERNA PHARMACEUTICALS - AS OF JUNE 30, 2019, HAD $345.3 MILLION IN CASH, CASH EQUIVALENTS, & HELD-TO-MATURITY INVESTMENTS VERSUS $302.6 MILLION AS OF DEC 31, 2018.DICERNA - SEES CURRENT CASH, CASH-EQUIVALENTS, HELD-TO-MATURITY INVESTMENTS TO BE SUFFICIENT TO FUND EXECUTION OF CURRENT CLINICAL, OPERATING PLAN BEYOND 2020.  Full Article

Dicerna Receives Breakthrough Therapy Designation For Dcr-Phxc
Monday, 15 Jul 2019 

July 15 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA RECEIVES BREAKTHROUGH THERAPY DESIGNATION FOR DCR-PHXC FOR TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1).  Full Article

Dicerna To Begin Clinical Development Of DCR-A1AT For Treatment Of Patients With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Tuesday, 2 Jul 2019 

July 2 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA™ TO BEGIN CLINICAL DEVELOPMENT OF DCR-A1AT FOR TREATMENT OF PATIENTS WITH ALPHA-1 ANTITRYPSIN DEFICIENCY-ASSOCIATED LIVER DISEASE.DICERNA PHARMACEUTICALS INC - PLANS TO INITIATE MULTICENTER PHASE 1/2 TRIAL IN Q3 OF 2019.DICERNA PHARMACEUTICALS INC - PLANS TO CONDUCT STUDY IN UP TO 16 SITES ACROSS EUROPE, WITH FIRST CLINICAL TRIAL SITE IN SWEDEN.  Full Article

Dicerna Pharma Posts Q1 Loss Per Share Of $0.38
Friday, 10 May 2019 

May 9 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA™ REPORTS FIRST QUARTER 2019 FINANCIAL AND OPERATING RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.38.Q1 EARNINGS PER SHARE ESTIMATE $-0.23 -- REFINITIV IBES DATA.AS OF MARCH 31 HAD $371.2 MILLION IN CASH, CASH EQUIVALENTS AND HELD-TO-MATURITY INVESTMENTS.BELIEVES CURRENT CASH,OTHERS WILL BE SUFFICIENT TO FUND EXECUTION OF ITS CURRENT CLINICAL AND OPERATING PLAN BEYOND 2020.EXPECTS ITS OVERALL RESEARCH AND DEVELOPMENT EXPENSE TO CONTINUE TO INCREASE FOR FORESEEABLE FUTURE.  Full Article

Dicerna Submits Updated IND Application For DCR-PHXC For Treatment Of Primary Hyperoxaluria
Thursday, 2 May 2019 

May 2 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA™ SUBMITS UPDATED IND APPLICATION FOR DCR-PHXC FOR TREATMENT OF PRIMARY HYPEROXALURIA (PH) FOR THE PHYOX™2 PIVOTAL TRIAL.DICERNA PHARMACEUTICALS INC - UPDATED IND APPLICATION FOR DCR-PHXC REFLECTS ALIGNMENT WITH FDA ON PATH TO FULL APPROVAL FOR TREATMENT OF PH1.DICERNA PHARMACEUTICALS INC - DISCUSSIONS NOW FOCUSING ON APPROPRIATE ENDPOINTS FOR PH2 AND PH3.DICERNA PHARMACEUTICALS INC - COMPANY EXPECTS TO BEGIN ENROLLING PATIENTS TO PHYOX2 TRIAL IN Q2 OF 2019.  Full Article

Dicerna Pharma Announces Initiation Of Participant Screening For Phyox2 Pivotal Trial In PH1 And PH2
Friday, 29 Mar 2019 

March 29 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA™ ANNOUNCES THE PRESENTATION OF UPDATED DATA DEMONSTRATING UTILITY OF ITS LEAD COMPOUND DCR-PHXC IN TREATING PRIMARY HYPEROXALURIA TYPE 1 (PH1) AND TYPE 2 (PH2).DICERNA PHARMACEUTICALS INC - COMPANY ANNOUNCES INITIATION OF PARTICIPANT SCREENING FOR PHYOX2 PIVOTAL TRIAL IN PH1 AND PH2.DICERNA PHARMACEUTICALS INC - PHYOX™1 INVESTIGATORS REPORTED POTENT, DURABLE RESPONSE IN PHASE 1 STUDY IN PATIENTS WITH PH1 AND PH2.  Full Article

Boehringer Ingelheim Exercises Option On Second Hepatic Disease Target From Collaboration With Dicerna
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Dicerna Pharmaceuticals Inc ::BOEHRINGER INGELHEIM EXERCISES OPTION ON SECOND HEPATIC DISEASE TARGET FROM RESEARCH COLLABORATION WITH DICERNA.DICERNA PHARMACEUTICALS INC - OPTION IS SECOND TARGET UNDER TWO COMPANIES' RESEARCH COLLABORATION AND LICENSE AGREEMENT.DICERNA PHARMACEUTICALS - COLLABORATION SEEKS TO DEVELOP NOVEL TREATMENTS FOR CHRONIC LIVER DISEASES, INCLUDING NONALCOHOLIC STEATOHEPATITIS (NASH).DICERNA PHARMACEUTICALS - UNDER AGREEMENT TERMS, BOEHRINGER INGELHEIM WILL BE RESPONSIBLE FOR FUTURE CLINICAL DEVELOPMENT OF THE THERAPEUTIC TARGET.  Full Article

Dicerna Pharmaceuticals Says Co, Boehringer Ingelheim International GmbH Entered Additional Target Agreement
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA PHARMACEUTICALS INC - ON DEC 31, CO, AND BOEHRINGER INGELHEIM INTERNATIONAL GMBH, ENTERED AN ADDITIONAL TARGET AGREEMENT - SEC FILING.DICERNA PHARMACEUTICALS INC - COMPANY HAD CASH, CASH EQUIVALENTS, AND HELD-TO-MATURITY INVESTMENTS OF APPROXIMATELY $302.6 MILLION AS OF DECEMBER 31, 2018..DICERNA PHARMACEUTICALS - BOEHRINGER INGELHEIM INTERNATIONAL GMBH WILL PAY CO A NON-REFUNDABLE UPFRONT PAYMENT OF $5.0 MILLION.DICERNA PHARMACEUTICALS - ATA PROVIDES BI WITH OPTION TO ADD DEVELOPMENT OF PRODUCT CANDIDATES TARGETING A FURTHER ADDITIONAL GENE FOR A 3-YEAR PERIOD.DICERNA PHARMACEUTICALS - CO ELIGIBLE TO RECEIVE UP TO $170.0 MILLION IN POTENTIAL DEVELOPMENT AND COMMERCIAL MILESTONES RELATED TO ADDITIONAL TARGET.DICERNA PHARMACEUTICALS - ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS ON POTENTIAL GLOBAL NET SALES, SUBJECT TO CERTAIN ADJUSTMENTS, IN MID-SINGLE DIGITS.DICERNA - BELIEVES CASH, CASH-EQUIVALENTS, PAYMENTS FROM LILLY & REDUCED BY CASH PAYMENT TO ALNYLAM IS SUFFICIENT TO FUND OPERATING PLAN BEYOND 2020.DICERNA PHARMACEUTICALS -ATA PROVIDES FOR DELIVERY OF A REPLACEMENT CANDIDATE TO BI IF A PRODUCT CANDIDATE OR ATA FAILS AT SOME STAGES OF DEVELOPMENT.  Full Article

Dicerna Pharmaceuticals Inc - Co Will Be Added To Nasdaq Biotechnology Index .
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Dicerna Pharmaceuticals Inc ::DICERNA PHARMACEUTICALS INC - COMPANY WILL BE ADDED TO NASDAQ BIOTECHNOLOGY INDEX EFFECTIVE PRIOR TO MARKET OPEN ON MONDAY, DECEMBER 24, 2018..  Full Article